Publication Highlight: Activation of the IKK2/NF-κB pathway in VSMCs inhibits calcified vascular stiffness in Chronic Kidney Disease
Publication Highlight: Activation of the IKK2/NF-κB pathway in VSMCs inhibits calcified vascular stiffness
Come and experience the cutting-edge world of neuroscience with Scintica at SFN 2023, the Society for Neuroscience’s premier event of the year! We cordially invite you to visit us in BOOTH 2403 and discover firsthand how Scintica’s cutting-edge tools and technologies can empower your research endeavors, enhance data acquisition and analysis, and accelerate scientific discoveries. Engage with our experts who will be delighted to discuss your specific needs and guide you towards the most suitable solutions tailored to your research goals.
SFN 2023 will be a dynamic platform buzzing with thought-provoking presentations, interactive sessions, and networking opportunities with the brightest minds in neuroscience. As an exhibitor, Scintica is committed to fostering partnerships, driving innovation, and advancing the boundaries of our understanding of the brain and nervous system.
We eagerly await for you to join us as we pave the way towards groundbreaking discoveries and together shape the limitless possibilities of neuroscience research!
When does the Meeting Take Place?
Saturday, November 11 – Wednesday, November 15
Where is this year’s SFN 2023 Annual Meeting?
Walter E. Washington Convention Center. Washington, DC
Publication Highlight: Activation of the IKK2/NF-κB pathway in VSMCs inhibits calcified vascular stiffness
Application Note: Bioprinting 3D Multi-cellular Cartilage Spheroids Using Laser-Assisted Technology View Paper Here
Publication Highlight: Single High-Dose Erythropoietin Disrupts Bone Homeostasis via Osteoclastogenic Pathways View Paper
Publication Highlight: Long-Term Optical Imaging Reveals Bone Marrow Clearance and Extramedullary Escape in
Publication Highlight: Overexpression of IL-32γ inhibits skin cancer formation through suppression of NF-κB
Publication Highlight: The role of phosphodiesterase 5 inhibitors in attenuating obesity-induced metabolic disorders